- Home
- IMVT
IMVT
Immunovant Inc.
as 01-17-2025 4:00pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 3.6B | IPO Year: | N/A |
| Target Price: | $46.11 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.41 - $41.38 | Next Earning Date: | 02-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | IMVT | Director10% Owner | Jan 13 '25 | Buy | $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Jan 8 '25 | Sell | $24.10 | 4,105 | $98,930.50 | 327,064 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Jan 8 '25 | Sell | $24.10 | 5,105 | $123,030.50 | 972,992 | |
| Hughes Douglas J. | IMVT | Director | Dec 2 '24 | Sell | $28.54 | 5,425 | $154,829.50 | 119,585 | |
| Pande Atul | IMVT | Director | Dec 2 '24 | Sell | $28.54 | 7,750 | $221,185.00 | 86,663 | |
| Macias William L. | IMVT | Chief Medical Officer | Nov 20 '24 | Sell | $25.45 | 3,353 | $85,333.85 | 361,791 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Nov 20 '24 | Sell | $25.45 | 4,174 | $106,228.30 | 327,064 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Nov 20 '24 | Sell | $25.45 | 3,650 | $92,892.50 | 319,228 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Nov 20 '24 | Sell | $25.45 | 16,692 | $424,811.40 | 972,992 | |
| Levine Mark S. | IMVT | Chief Legal Officer | Oct 23 '24 | Sell | $29.53 | 4,361 | $128,780.33 | 319,228 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each
GlobeNewswire
6 days ago
Immunovant Announces $450 Million Private Placement
MT Newswires
16 days ago
Wolfe Research Downgrades Immunovant to Peer Perform From Outperform
Simply Wall St.
19 days ago
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
TipRanks
a month ago
Immunovant price target lowered to $45 from $47 at Wells Fargo
Insider Monkey
2 months ago
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?
Thomson Reuters StreetEvents
2 months ago
Q2 2024 Roivant Sciences Ltd Earnings Call
Zacks
2 months ago
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.